Postdoctoral Research Scientist
The successful candidate will work on the mechanisms of cell fate decisions in vivo during development, using single cell multi-omics and computational approaches. The postholder will isolate single cells from postimplantation mouse embryos or mouse and human gastruloids.
The post holder will sequence cells with multi-omics techniques (scNMT-seq and others that are being developed) and analyse the results using advanced computational methods such as MOFA. The jobholder will also attempt to manipulate epigenetic states and cell fate in vitro and in vivo using CRISPR/cas9 genetic and epigenetic editing.
The ideal candidate must have a PhD in developmental biology, molecular biology, genetics or related biological discipline and must be able to demonstrate experience in molecular biology including epigenome sequencing and computational approaches preferably in small cell numbers or single cells. Extensive knowledge of epigenetics and mammalian developmental biology are essential to be successful in this position.
The funding for this position is available for three years in the first instance.
For more information on the work of the group, please visit:
Full details of the position can be found here.
Starting salary is £30,751 per annum to £32,116 per annum depending on experience.
On applying please quote reference PDR-WR-LTC
Closing date for completed applications is Friday, 31 August 2018.
NO AGENCIES PLEASE
The Babraham Institute is a Disability Confident Employer and has a positive approach to employing disabled people.
The Babraham Institute receives strategic funding from the Biotechnology and Biological Sciences Research Council and is an Equal Opportunities Employer.
Please complete the following before submitting your application:
Please submit your Cover letter
Please submit your CV
Please submit your completed Application form
Equal Opportunities Monitoring Form
Please submit your completed Equal Opportunities Monitoring Form
Job description, Person specification and Benefits Statement